Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun 11;81(12):555-562.
doi: 10.1093/ajhp/zxae008.

Implementation of clopidogrel pharmacogenetic clinical decision support for a preemptive return of results program

Christina L Aquilante  1   2 , Katy E Trinkley  1   3 , Yee Ming Lee  1   4 , Kristy R Crooks  1   5 , Emily C Hearst  1   6 , Simeon M Heckman  6 , Kaitlyn W Hess  6 , Elizabeth L Kudron  1   7 , James L Martin  1   2 , Carolyn T Swartz  6 , David P Kao  1   8
Affiliations

Implementation of clopidogrel pharmacogenetic clinical decision support for a preemptive return of results program

Christina L Aquilante et al. Am J Health Syst Pharm. .

Abstract

Purpose: To describe our experiences implementing and iterating CYP2C19 genotype-guided clopidogrel pharmacogenetic clinical decision support (CDS) tools over time in the setting of a large health system-wide, preemptive pharmacogenomics program.

Summary: Clopidogrel-treated patients who are genetically predicted cytochrome P450 isozyme 2C19 (CYP2C19) intermediate or poor metabolizers have an increased risk of atherothrombotic events, some of which can be life-threatening. The Clinical Pharmacogenetics Implementation Consortium provides guidance for the use of clopidogrel based on CYP2C19 genotype in patients with cardiovascular and cerebrovascular diseases. Our multidisciplinary team implemented an automated, interruptive alert that fires when clopidogrel is ordered or refilled for biobank participants with structured CYP2C19 intermediate or poor metabolizer genomic indicators in the electronic health record. The implementation began with a narrow cardiovascular indication and setting and was then scaled in 4 primary dimensions: (1) clinical indication; (2) availability across health-system locations; (3) care venue (e.g., inpatient vs outpatient); and (4) provider groups (eg, cardiology and neurology). We iterated our approach over time based on evolving clinical evidence and proactive strategies to optimize CDS maintenance and sustainability. A key facilitator of expansion was socialization of the broader pharmacogenomics initiative among our academic medical center community, accompanied by clinician acceptance of pharmacogenetic alerts in practice.

Conclusion: A multidisciplinary collaboration is recommended to facilitate the use of CYP2C19 genotype-guided antiplatelet therapy in patients with cardiovascular and cerebrovascular diseases. Evolving clopidogrel pharmacogenetic evidence necessitates thoughtful iteration of implementation efforts and strategies to optimize long-term maintenance and sustainability.

Keywords: CYP2C19; clinical decision support; clopidogrel; cytochrome P450 isozyme 2C19; implementation; pharmacogenetics; pharmacogenomics.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Screenshot of patient genomic indicators displayed in the UCHealth electronic health record.
Figure 2.
Figure 2.
Clinical decision support alert for CYP2C19 and clopidogrel displayed to prescribers at UCHealth.
Figure 3.
Figure 3.
Screenshot of page on the CCPM Biobank’s clinician education website providing information on clopidogrel and CYP2C19.
See this image and copyright information in PMC

References

    1. Botton MR, Whirl-Carrillo M, Del Tredici AL, et al. PharmVar GeneFocus: CYP219. Clin Pharmacol Ther. 2021;109(2):352-366. doi:10.1002/cpt.1973 - DOI - PMC - PubMed
    1. Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010;304(16):1821-1830. doi:10.1001/jama.2010.1543 - DOI - PMC - PubMed
    1. Pereira NL, Rihal C, Lennon R, et al. Effect of CYP2C19 genotype on ischemic outcomes during oral P2Y12 inhibitor therapy: a meta-analysis. JACC Cardiovasc Interv. 2021;14(7):739-750. doi:10.1016/j.jcin.2021.01.024 - DOI - PMC - PubMed
    1. Cavallari LH, Lee CR, Beitelshees AL, et al. Multisite investigation of outcomes with implementation of CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention. JACC Cardiovasc Interv. 2018;11(2):181-191. doi:10.1016/j.jcin.2017.07.022 - DOI - PMC - PubMed
    1. Claassens DMF, Vos GJA, Bergmeijer TO, et al. A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI. N Engl J Med. 2019;381(17):1621-1631. doi:10.1056/NEJMoa1907096 - DOI - PubMed

MeSH terms